CENPF
Overview
CENPF encodes centromere protein F (also known as mitosin), a large nuclear matrix protein involved in kinetochore assembly and mitotic progression. CENPF expression has been associated with tumor cell proliferation and poor prognosis in multiple cancer types including glioma. In the context of epigenetic evolution in IDH-mutant glioma, CENPF is a downstream transcriptional target of the HOXD13 master regulator that becomes aberrantly activated at tumor recurrence.
Alterations observed in the corpus
- CENPF is a HOXD13 target gene that becomes epigenetically activated through treatment-associated DNA hypomethylation in IDH-mutant astrocytoma at recurrence; associated with glioma prognosis and cell proliferation PMID:38117484.
Cancer types (linked)
- DIFG/ASTR/GB: CENPF upregulation linked to HOXD13 activation at glioma recurrence, particularly in IDH-mutant astrocytomas that have undergone treatment-driven epigenetic evolution; associated with proliferative phenotype PMID:38117484.
Co-occurrence and mutual exclusivity
- CENPF upregulation co-occurs with HOXD13 activation, PCNA upregulation, and HOXA7 upregulation as part of a HOXD13-driven transcriptional program at IDH-mutant glioma recurrence PMID:38117484.
Therapeutic relevance
- CENPF has been proposed as a potential therapeutic target in gliomas given its role in mitotic progression; its upregulation at recurrence may mark a proliferative state amenable to anti-mitotic strategies PMID:38117484.
Open questions
- Whether CENPF expression level is independently prognostic in IDH-mutant astrocytoma after controlling for IDH status and HOXD13 activation has not been formally tested.
Sources
This page was processed by crosslinker on 2026-05-04.